Drug Profile
Arsenic trioxide - Biosenic
Alternative Names: ArsciCor; ArsciMed; Arscimed; OATO - BiosenicLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Medsenic
- Developer Medsenic; Nantes University Hospital; Phebra
- Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Graft-versus-host disease; Systemic lupus erythematosus
- Preclinical Encephalomyelitis; Multiple sclerosis; Systemic scleroderma
Most Recent Events
- 12 Mar 2024 Efficacy and adverse events data from a phase II trial in Graft-versus-host disease released by BioSenic
- 02 Feb 2024 BioSenic plans to file an IND application with the US FDA for phase III trial in chronic graft versus host disease (Adjunctive treatment, First-line therapy) (PO)
- 31 Jan 2024 BioSenic plans a phase III trial for chronic graft versus host disease (Adjunctive treatment, First-line therapy) (PO) in the second quarter of 2024